Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Studie opravy tkáně u zánětlivého onemocnění střev využívající organoidní technologii (ORGANOIDS)

18. září 2026 aktualizováno: Assistance Publique Hopitaux De Marseille

Inflammatory Bowel Diseases (IBD) are chronic inflammations of the gastrointestinal tract. Regardless of the etiology, a common trait of IBD pathogenesis is the inflammatory damage inflicted on the intestinal mucosa and the loss of intestinal epithelial barrier integrity. Therefore, understanding the mechanisms that govern IEC's capacity to maintain barrier function and to orchestrate mucosal healing is considered a major goal in translational research. The investigators are interested in understanding how the inflammatory environment present in the intestinal mucosa, of IBD patients influences epithelial cells capacity to govern repair. The complexities of the cytokine and metabolic milieu present in IBD patients render the study of the contribution of each cytokine, metabolite, and intracellular pathway extremely complicated. Therefore, most of the processes that govern tissue regeneration are studied with the use of mouse models that recapitulate one or multiple features of IBD and allow for genetical modifications of the gene and pathway of interest. While mouse models are uniquely suited to study the complex crosstalk between the immune system, the microbiota, and the intestinal epithelia, they introduce the important problem of species-specific differences, which can hamper the translational value of mouse studies.

To overcome these shortcomings, the investigators propose to explore the influence of cytokines and metabolites in digestive organoids derived from patients and controls. Importantly, it was demonstrated that gene expression and innate immune responses are altered in primary organoids derived from patients with IBD, including altered ability to proliferate, respond to cytokines, metabolic capacity, and efficiently form organoids suggesting that major differences between patient's and control's epithelial cell biology can be faithfully replicated in this system.

Given these premises, the investigators propose the following objectives:

Primary objective:

The main objective of this study is to establish that patient's epithelial cells from inflamed mucosae have decreased ability to repair the intestinal mucosa, as compared to epithelial cells from non-inflamed regions in the same patient, or to control subject with no inflammatory digestive diseases.

The investigators will explore this question both deriving organoids from clinical samples and exposing them to pro inflammatory cytokines and metabolites in vitro, as well as by analyzing repair responses from the aforementioned clinical samples ex vivo.

Secondary objective

The secondary goals of this study are:

- To compare organoids derived from: epithelia in inflamed mucosa of IBD patients, epithelia in non-inflamed mucosa of IBD patients, and epithelia from the mucosa of non-IBD controls in their capacity to mount a repair response in response to inflammatory cytokines or luminal metabolites.

Namely the investigators will evaluate the following parameters:

  • Their capacity to proliferate.
  • Their ability to survive treatment with pro-inflammatory cytokines
  • The activation of intracellular pathways associated with cell death.
  • Their overall metabolic activity.
  • The balance between stem and differentiated epithelial cell types.
  • The transcriptional activation of protective pathways such as those associated with proliferation, migration, differentiation and cell survival.
  • To evaluate hallmarks of tissue repair in biopsies derived from epithelia in inflamed mucosa of IBD patients, epithelia in non-inflamed mucosa of IBD patients, and epithelia from the mucosa of non-IBD controls, and to correlate them to the levels of inflammatory cytokines, luminal metabolites and overall disease severity. Namely the investigators will evaluate the following parameters:
  • The abundance of proliferating cells.
  • The activation of intracellular pathways associated with cell death and survival.
  • Their overall metabolic activity.
  • The balance between stem and differentiated epithelial cell types.
  • The transcriptional activation of protective pathways such as those associated with proliferation, migration, differentiation and cell survival.

Přehled studie

Postavení

Nábor

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Odhadovaný)

60

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

For IBD group the inclusion criteria will be:

  • Patients of either sex aged 18 years or older
  • Patient that have read the information form and signed consent
  • Patient covered with health insurance
  • Patients with Crohn's Disease or ulcerative colitis in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria, regardless of the level, severity of the disease or duration of disease progression.
  • Patients with colonic involvement of Crohn's disease or ulcerative colitis
  • Patients undergoing a screening colonoscopy in the context of IBD disease follow-up OR undergoing intestinal resection for IBD disease aggravation

For control group the inclusion criteria will be:

  • Patients of either sex aged 18 years or older
  • Patient that have read the information form and signed consent
  • Patient covered with health insurance
  • Patients undergoing a screening colonoscopy in the context of a family history of colonic neoplasia, follow-up of colonic polyps or functional intestinal disorders OR undergoing intestinal resection for intestinal neoplasia, occlusive syndrome or colostomy

The non-inclusion criteria for IBD group will be:

  • Contraindication to the anaesthetic or colonoscopy procedure
  • Patients without colonic involvement of Crohn's disease or ulcerative colitis
  • Patients of Adults without legal capacity
  • Patients in Health and Social Establishments
  • Persons in emergency situations
  • Persons deprived of their liberty
  • Non-affiliated to a social security scheme
  • Absence or refusal of the informed consent

The non-inclusion criteria for control group will be:

  • IBD disease revealed during colonoscopy or gastrointestinal resection
  • Patient suffering from Immune-Mediated Inflammatory Diseases (IMIDs)
  • Contraindication to the anaesthetic or colonoscopy procedure
  • Patients of Adults without legal capacity
  • Patients in Health and Social Establishments
  • Persons in emergency situations
  • Persons deprived of their liberty
  • Non-affiliated to a social security scheme
  • Absence or refusal of the informed consent

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Základní věda
  • Přidělení: Nerandomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Falešný srovnávač: Control group

Patients of either sex aged 18 years or older and undergoing a screening colonoscopy in the context of a family history of colonic neoplasia, follow-up of colonic polyps or functional intestinal disorders OR undergoing intestinal resection for intestinal neoplasia, occlusive syndrome or colostomy

Collection of 10 colonic biopsies in healthy tissue

Collection of a portion of healthy mucous membrane

Experimentální: IBD group

Patients of either sex aged 18 years or older with Crohn's Disease or ulcerative colitis in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria, regardless of the level, severity of the disease or duration of disease progression or patients undergoing a screening colonoscopy in the context of IBD disease follow-up OR undergoing intestinal resection for IBD disease aggravation

Collection of a portion of healthy mucous membrane

Collection of 10 colonic biopsies in IBD inflamed tissue

Collection of a portion of IBD inflamed mucous membrane

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Repair status of IBD patient's epithelial cells from inflamed mucosae
Časové okno: From enrollmet to the end of following at 1 month

To establish that patient's epithelial cells from inflamed mucosae have decreased ability to repair the intestinal mucosa, as compared to epithelial cells from non-inflamed regions in the same patient, or to control subject with no inflammatory digestive diseases

From enrollmet to the end of following at 1 month

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Evaluate the molecular mechanism involved in the reduced capacity of epithelial cells of IBD patients to repair intestinal mucosa
Časové okno: From enrollment to the end of following at 1 month

Evaluation of:

  • The capacity epithelial cells of IBD patients to proliferate: ratio of Ki67+cells.
  • The ability of epithelial cells of IBD patients to survive treatment with pro-inflammatory cytokines: ratio between live and dead organoids.
  • The activation of intracellular pathways associated with cell death: relative quantification of biochemical activation of 1) apoptotic caspases,2) pyroptosis effectors (GSDMs),3) Necroptosis effectors (MLKL).
  • The balance between stem and differentiated epithelial cell types: the relative gene expression of the stemness associated genes LGR5, OLFM4, and the hallmark genes of differentiated cell types AQP8, MUC2, LYZ1, CHGA).
From enrollment to the end of following at 1 month
Genetically determine the involvement of cell death and protective pathways that reduce repair capacity in patients.
Časové okno: From enrollment to the end of following at 1 month

After a genetically modify with CRISPR-CAS9 technology:

  • The capacity of modified epithelial cells of IBD patients to proliferate: ratio of Ki67+cells.
  • The ability of modified epithelial cells of IBD patients to survive treatment with pro-inflammatory cytokines: ratio between live and dead organoids.
  • The activation of intracellular pathways associated with cell death: relative quantification of biochemical activation of 1) apoptotic caspases,2) pyroptosis effectors (GSDMs),3) Necroptosis effectors (MLKL).
  • The balance between stem and differentiated epithelial cell types: the relative gene expression of the stemness associated genes LGR5, OLFM4, and the hallmark genes of differentiated cell types AQP8, MUC2, LYZ1, CHGA).
From enrollment to the end of following at 1 month
3. Explore the activation of molecular mechanisms identified in patient biopsies and correlate them with the inflammatory environment present in the patient's tissues
Časové okno: From enrollment to the end of following at 1 month
  • Proliferation in FFPE biopsies and RNA from RNAlater fixed biopsies: Ki67 upregulation by immunohistochemistry (IHC), PCNA gene expression, Proliferation transcriptional signature by RNAseq etc…).
  • Cell death by biochemical analysis of cell death pathways by Western Blot (WB) and IHC in flash frozen biopsies: relative quantification of biochemical activation of 1) apoptotic caspases; 2) pyroptosis effectors (GSDMs); 3) Necroptosis effectors (MLKL).
  • Differentiation status of epithelial cells from DMSO conserved biopsies: staining of cell type markers by IHC, scRNAseq of dissociated epithelial cells.
  • The metabolic landscape of epithelial cells in flash frozen biopsies: the metabolome of the cells.
From enrollment to the end of following at 1 month

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

24. července 2025

Primární dokončení (Odhadovaný)

24. března 2027

Dokončení studie (Odhadovaný)

24. března 2027

Termíny zápisu do studia

První předloženo

28. ledna 2025

První předloženo, které splnilo kritéria kontroly kvality

28. ledna 2025

První zveřejněno (Aktuální)

3. února 2025

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

21. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

18. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • RCAPHM24_0062
  • 2024-A00510-47 (Jiný identifikátor: EUdraCT)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .